Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Stockton › NPI 1083707822
Physician

Vitreo-Retinal Medical Group, INC.

Vitreo-Retinal Medical Group, INC. was paid $11.61M by Medicaid between Jan 2018 and Nov 2024, across 16 billing codes. Its largest line is 67028, Intravitreal injection of a pharmacologic agent — 38% of everything it billed.

33Billing provider infoVITREO-RETINAL MEDICAL GROUP, INC.
STOCKTON, CA 95219
33aNPI1083707822assigned 10/02/2006
33bProvider typeOphthalmology Physician
28Total paid$11.61M
24GClaims54,602
24DCodes billed16
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers

Next to other Ophthalmology Physician providers in California

Rank by total paid#5 of 759
Median peer was paid$35K
This provider vs. median329×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official PEARLMAN, JOEL controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20184,761$632K
20195,082$615K
20206,662$873K
202110,173$1.88M
20229,962$2.64M
20239,147$2.36M
2024incomplete8,815$2.60M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
67028 Intravitreal injection of a pharmacologic agent 38% 14,345 10,790 $4.47M
J0178 Injection, aflibercept, 1 mg 38% 1,747 1,698 $4.38M
92134 4.9% 16,826 16,163 $573K
Q5128 Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg 4.3% 479 342 $504K
J2778 Injection, ranibizumab, 0.1 mg 4.0% 444 427 $466K
92250 2.2% 5,734 5,607 $261K
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 2.2% 3,790 3,645 $257K
J9035 Injection, bevacizumab, 10 mg 2.2% 2,496 2,265 $253K
92235 2.1% 3,000 2,946 $243K
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 1.4% 5,023 4,912 $165K
67228 <1% 69 67 $23K
92014 Ophthalmological services: medical examination and evaluation, comprehensive, established patient <1% 504 489 $7K
4 more codes
99204 Doctor's office visit, new patient (more involved) <1% 61 $5K
99203 Doctor's office visit, new patient (routine) <1% 57 $5K
76512 <1% 14 $734.25
J7999 Compounded drug, not otherwise classified <1% 13 $77.51

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPEARLMAN, JOEL (PRESIDENT)
Same official

Other billing entities under PEARLMAN, JOEL

Full network →

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.